Laura Palmieri

Laura Palmieri

Auto-generated profile, based on publicly available information

Laura Palmieri

Academic, Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LPLaura Palmieri
Laura Palmieri
Helena MalvezziHelena Malvezzi
Helena Malvezzi
BABruna Cestari de Azevedo
Bruna Cestari de Azevedo
SPSergio Podgaec
Sergio Podgaec
Endometriosis is a prevalent gynecological condition with deleterious effects on women’s quality of life in terms of physical, emotional, and social compromise. It is an inflammatory disease characterized by the presence of endometrial-like tissue outside the uterus, and its presentation varies from superficial peritoneal lesions to deep infiltrative endometriosis and ovarian endometrioma. In our previous study, endometriotic lesions were implicated in cellular senescence as their inflammatory pattern could potentially compromise surrounding tissue integrity, thereby inducing a senescent state in cells. P16Ink4a and lamin b1 are biomarkers used to assess cellular senescence. Indirect immunofluorescence staining is a broad technique used to assess cellular structure and behavior driven by protein–protein interactions that provide valuable information about cell functioning. The etiopathogeny of endometriosis is not completely understood and diagnostic approaches still rely on invasive methods; therefore, it is important to use validated methods to increase our understanding of the disease and the development of novel diagnostic tools. However, indirect immunofluorescence protocols are often tissue specific and, if neglected, can lead to misinterpretation of results. Moreover, no valid endometriotic tissue-specific colocalization immunofluorescence protocols have been established. Thus, we have validated a well-funded and suitable protocol to allow precise evaluation of the three presentations of endometriosis lesions using indirect immunofluorescence aiming to support further investigations in endometriosis lesions.

29 May 2025 in Cancer Prevention Research
Verified
Journal Article
Open access
LPLaura Palmieri
Laura Palmieri
FZFernando T. Zamuner
Fernando T. Zamuner
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
KGKeerthana Gosala
Keerthana Gosala
EWEli Winkler
Eli Winkler
RGRafael Guerrero-Preston
Rafael Guerrero-Preston
Cervical cancer is one of the most common cancers in women. Despite progress in prevention and success in early detection through cytologic screening and human papillomavirus (HPV) detection, there remains a challenge in triaging women appropriately to colposcopy and biopsy. We sought to validate the CervicalMethDx test, a precision DNA methylation classifier for cervical cancer detection, as a reflex test in women with HPV-positive samples. A blinded retrospective study was performed on well-characterized samples in PreservCyt media from a large referral clinical laboratory in the United States. DNA methylation was assessed in three gene promoters (ZNF516, FKBP6, and INTS1) and a control gene (β-actin) by quantitative real-time methylation-specific PCR (qMSP) analysis, using machine learning algorithms. We compared DNA methylation levels in HPV-positive patients presenting with lesions in the Pap test and cervical intraepithelial neoplasia grade 2 (CIN2) or CIN3 histologic diagnosis with DNA methylation levels in HPV-positive patients with lesions in the Pap test but no intraepithelial lesion or malignancy. The CervicalMethDx test correctly classified 95% of the CIN2 samples (n = 210), with 91% sensitivity, 100% specificity, and an area under the ROC curve (AUC) of 0.96, and 94% of CIN3 samples (n = 141), with 90% sensitivity, 100% specificity, and an AUC of 0.96. Moreover, the CervicalMethDx test correctly classified 94% of combined CIN2/CIN3 samples (n = 351), with 93% sensitivity, 97% specificity, and an AUC of 0.96. CervicalMethDx demonstrated strong discriminatory power for identifying CIN2/CIN3 risk and may complement current triage strategies for colposcopy referral. Prospective, population-based studies, including those in low-resource settings, are needed for further evaluation. Prevention Relevance: The CervicalMethDx test integrates DNA methylation analysis and machine learning to improve early detection of high-grade cervical lesions (high-grade squamous intraepithelial lesions), offering a noninvasive, cost-effective screening tool. Enhanced risk stratification and overtreatment reduction expand equitable access to precision prevention programs. Further validation will clarify CervicalMethDx’s alignment with global cervical cancer prevention strategies.

30 July 2025 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
LPLaura Palmieri
Laura Palmieri
Helena MalvezziHelena Malvezzi
Helena Malvezzi
BABruna Cestari de Azevedo
Bruna Cestari de Azevedo
EPEduardo Varejão Díaz Placencia
Eduardo Varejão Díaz Placencia
EEliane Antonioli
Eliane Antonioli
SPSérgio Podgaec
Sérgio Podgaec
Highlights ■ MMP-1, MMP-2, and MMP-3 are upregulated in endometriotic lesions. ■ The study findings suggest a senescence-associted secretory phenotype in endometriosis. ■ The study findings support targeting senescence pathways in endometriosis. ABSTRACT Objective: To investigate the roles of cellular senescence and dysfunctional extracellular matrix metalloproteinases (MMPs) in perpetuating chronic inflammation and facilitating the establishment of endometriotic lesions. By analyzing the MMP activity in the endometrial tissue and peritoneal fluid, we aimed to obtain novel insights into the molecular mechanisms

2 September 2025
Verified
Other
Open access
LPLaura Palmieri
Laura Palmieri
FZFernando T. Zamuner
Fernando T. Zamuner
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
KGKeerthana Gosala
Keerthana Gosala
EWEli Winkler
Eli Winkler
RGRafael Guerrero-Preston
Rafael Guerrero-Preston
Supplementary Table S4. Individual and cumulative standard deviation and proportion of variance explained by each of the three Principal Components of the CervicalMethDx test.

2 September 2025
Verified
Other
Open access
LPLaura Palmieri
Laura Palmieri
FZFernando T. Zamuner
Fernando T. Zamuner
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
KGKeerthana Gosala
Keerthana Gosala
EWEli Winkler
Eli Winkler
RGRafael Guerrero-Preston
Rafael Guerrero-Preston
Supplementary Table S1. Lower bounds for observed Sensitivity, Specificity and Power.

2 September 2025
Verified
Other
Open access
LPLaura Palmieri
Laura Palmieri
FZFernando T. Zamuner
Fernando T. Zamuner
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
KGKeerthana Gosala
Keerthana Gosala
EWEli Winkler
Eli Winkler
RGRafael Guerrero-Preston
Rafael Guerrero-Preston
Cervical cancer is one of the most common cancers in women. Despite progress in prevention and success in early detection through cytologic screening and human papillomavirus (HPV) detection, there remains a challenge in triaging women appropriately to colposcopy and biopsy. We sought to validate the CervicalMethDx test, a precision DNA methylation classifier for cervical cancer detection, as a reflex test in women with HPV-positive samples. A blinded retrospective study was performed on well-characterized samples in PreservCyt media from a large referral clinical laboratory in the United States. DNA methylation was assessed in three gene promoters (ZNF516, FKBP6, and INTS1) and a control gene (β-actin) by quantitative real-time methylation-specific PCR (qMSP) analysis, using machine learning algorithms. We compared DNA methylation levels in HPV-positive patients presenting with lesions in the Pap test and cervical intraepithelial neoplasia grade 2 (CIN2) or CIN3 histologic diagnosis with DNA methylation levels in HPV-positive patients with lesions in the Pap test but no intraepithelial lesion or malignancy. The CervicalMethDx test correctly classified 95% of the CIN2 samples (n = 210), with 91% sensitivity, 100% specificity, and an area under the ROC curve (AUC) of 0.96, and 94% of CIN3 samples (n = 141), with 90% sensitivity, 100% specificity, and an AUC of 0.96. Moreover, the CervicalMethDx test correctly classified 94% of combined CIN2/CIN3 samples (n = 351), with 93% sensitivity, 97% specificity, and an AUC of 0.96. CervicalMethDx demonstrated strong discriminatory power for identifying CIN2/CIN3 risk and may complement current triage strategies for colposcopy referral. Prospective, population-based studies, including those in low-resource settings, are needed for further evaluation.Prevention Relevance:The CervicalMethDx test integrates DNA methylation analysis and machine learning to improve early detection of high-grade cervical lesions (high-grade squamous intraepithelial lesions), offering a noninvasive, cost-effective screening tool. Enhanced risk stratification and overtreatment reduction expand equitable access to precision prevention programs. Further validation will clarify CervicalMethDx’s alignment with global cervical cancer prevention strategies.